Evidence map›Paper›PMID 42063557›Full record

ArticleiScience2026

F-53B exposure accelerates progression from preexisting fatty liver to non-alcoholic steatohepatitis and hepatic fibrosis.

Chunhua Hu, Liu Wu, Zehui Zhang, Yu Liu, Huihui Yang, Jian Zhou, Yongming Wu, Qiyu Wang

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chunhua HuSchool of Resources and Environment, Nanchang University, Nanchang 330031, China.
Liu WuSchool of Resources and Environment, Nanchang University, Nanchang 330031, China.
Zehui ZhangSchool of Water Resources & Environmental Engineering, East China University of Technology, Nanchang 330013, China.
Yu LiuInstitute of Resources and Environment, Jiangxi Academy of Sciences, Nanchang 330012, China.
Huihui YangDepartment of Nephrology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430000, China.
Jian ZhouInstitute of Medicine and Health, Jiangxi Academy of Sciences, Nanchang 330012, China.
Yongming WuInstitute of Resources and Environment, Jiangxi Academy of Sciences, Nanchang 330012, China.
Qiyu WangInstitute of Medicine and Health, Jiangxi Academy of Sciences, Nanchang 330012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

6:2 Chlorinated polyfluoroalkyl ether sulfonate (F-53B) is prevalent in the environment, yet its effect on pre-existing metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Using adult male zebrafish with high-fat diet-induced MASLD, we investigated the hepatotoxicity of F-53B. Following exposure, F-53B exacerbated hepatic damage in MASLD zebrafish, accelerating progression to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Notably, environmentally relevant concentrations altered lipid metabolism and MASH/fibrosis markers only in MASLD fish, while high concentrations were required to affect normal-diet fish. This heightened susceptibility stemmed from increased hepatic F-53B accumulation in diseased livers. Mechanistically, liver-type fatty acid-binding protein (L-FABP) knockdown in HepG2 cells reduced lipid accumulation, inflammatory and fibrotic responses, identifying L-FABP as a key F-53B transporter. These findings demonstrate that metabolic dysfunction increases vulnerability to F-53B hepatotoxicity, highlighting the need to consider pre-existing conditions in environmental pollutant risk assessment.

Indexed as

biological sciences

Identifiers

PMID42063557
PMCPMC13127485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.